不同剂量地西他滨序贯低剂量化疗方案治疗急性髓系白血病的效果观察  

The efficacy of different doses of decitabine sequential low-dose chemotherapy on acute myeloid leukemia

作　　者：蔡圣鑫[1] 王立华 邢丽娜[1] 张晓蕾[1] 李扬[1] 郭晓玲[1] 郭晓楠[1] 任金海[1] 

机构地区：[1]河北医科大学第二医院血液科,河北石家庄050000

出　　处：《广东医学》2018年第4期612-614,617,共4页Guangdong Medical Journal

基　　金：河北省科技计划项目(编号:152777181)

摘　　要：目的比较不同剂量的地西他滨序贯低剂量化疗方案治疗急性髓系白血病(AML)的疗效。方法对接受地西他滨序贯低剂量化疗方案治疗的65例AML患者进行回顾性疗效分析,并分为A组(20 mg/m^2×5 d)和B组(20 mg/m^2×3 d),比较两组的治疗缓解率。结果 37例A组患者中32例达到完全缓解,完全缓解率为86.5%,28例B组患者中18例达到完全缓解,完全缓解率为64.3%,两组差异有统计学意义(P=0.035)。A组患者的血小板(<20×10~9·L^(-1))和白细胞(<0.5×10~9·L^(-1))的中位持续时间与B组患者相比差异无统计学意义(P>0.05)。A组和B组患者中出现其他治疗相关的不良反应主要是感染(肺部感染和血流感染),其他出现较多的不良反应有乏力、便秘、食欲不振。两组患者经积极抗感染治疗均得到控制,两组均没有死亡病例,两组的不良反应相比均差异无统计学意义(P>0.05)。结论地西他滨20 mg/m^2×5 d序贯低剂量化疗治疗AML的疗效可能更好。Objective To compare the efficacies of different doses of decitabine sequential low -dose chemother- apies in the treatment of acute myeloid leukemia （AML）. Methods A retrospective analysis of 65 patients with AML treated with different doses of deeitabine sequential low - dose chemotherapies was performed. All patients were divided into Group A （20 mg/m2 x5 d） and Group B （20 mg/m2 x3 d）. The remission rate of the two groups was compared. Results In the Group A, 32 of 37 patients had complete remission, the complete remission rate was 86.5%. In the Group B, 18 of 28 patients had complete remission, and the complete remission rate was 64. 3%. The difference between the two groups was statistically significant （ P = 0. 035 ）. Compared group A with group B, the median durations of platelet 〈 20 x 10^9 · L- 1 and leukoeytes 〈 0. 5 x 10^9 · L- l were no significant difference （P 〉 0. 05 ）. Other treatment - related adverse events in patients of groups A and B were predominantly infections （ pulmonary infections and bloodstream infec- tions）. Other adverse reactions were more frequent with fatigue, constipation, loss of appetite. Infections of these patients were controlled by anti - infective therapy. There were no deaths in both groups, and there was no significant difference in adverse reactions between the two groups （P 〉 0.05）. Conclusion In the treatment of AML, decitabine 20 mg/m2 x 5 days sequential low -dose chemotherapy may be better.

关 键 词：地西他滨 不同剂量 急性髓系白血病 化疗 

分 类 号：R733.71[医药卫生—肿瘤]